Looking into the technicals, Novavax, Inc. (NASDAQ:NVAX) has scored 88% Buy indication. The stock is also flashing a Hold from the Barchart TrendSpotter trading system. Traders hoping to speculate on the NVAX’s short-term trajectory should know that short terms indicators for the stock averaged 80% Buy with an average daily trading volume over the past 20 days at 12068225 shares. NVAX stock has overall a 1% Buy signal considering medium term indicators and the 50-day average daily volume remained almost 8359229 shares. It’s also worth noting that the stock, whose average daily volume over the 100 days prior to this writing was 7316684 shares, is 100% Buy on the basis of long term indicators.
The share price is currently staying around the first support level of $2.2. Below this, the next support is placed in the zone of $2.14. Till the time, the NVAX stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 57.86 on daily chart, which may remain a cause for concern. If the price breaks below $2.14 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $2.34 mark may result into a pull-back move towards $2.42 level.
Novavax, Inc. (NVAX) is projected to climb by 90.75 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $10price as 12-month high target. This represents a whopping 340.53 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $3.5, which represents a return potential of 54.19 percent when compared to the closing price of the stock of $2.27 on Wednesday, January 09. The lowest price target for the stock is $1.5 — slightly more than -33.92 percent from NVAX’s current share price.
Here’s a rundown of insider trading activity for sense of Novavax, Inc. (NASDAQ:NVAX). The earliest insider trade took place on 07/31/2018. Glenn Gregory M gathered a total of 13.01 thousand shares of company at average share price of $0.88. The total for the purchase was set at $11.45 thousand. After this transaction, the President, R&D account balance stood at 60.22 thousand shares. The stock grew 161.36 percent since that insider purchase. On 05/14/2018, Erck Stanley C, President and CEO, purchased 100 thousand shares at a price per share of $1.65. This added 165 thousand shares to the insider’s fortune and the stock saw a 39.39 percent rally in value since the news became public. This transaction left 328.28 thousand shares in the President and CEO account. On 05/14/2018, SVP, CBO and CFO Trizzino John performed a purchase transaction worth $82 thousand. This purchase at $1.64 each has added 50 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded 40.24 percent increase since the transaction was reported. The insider now is left with 138.97 thousand shares remaining in the account. Glenn Gregory M, who performs the President, R&D job, bought 20 thousand shares for $32.8 thousand. The acquisition occurred on 05/14/2018 was priced at $1.64 per share. The share price soared 40.24 percent since the reporting date. Glenn Gregory M now left with a stake of 47.21 thousand NVAX stock worth $107.17 thousand after the insider buying.
NVAX shares dropped -0.03 points or -1.3 percent on Wednesday to $2.27 with a heavy trade volume of 9.562 million shares. After opening the session at $2.31, the shares went as high as $2.35 and as low as $2.21, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $868 million and now has 382.32 million shares outstanding. Novavax, Inc. (NVAX) stock has gained 10.73 percent of market value in 21 trading days.
Analysts at Ladenburg Thalmann, assumed coverage of Novavax, Inc. (NASDAQ:NVAX) with Buy recommendation, according to their opinion released on December 18. Analysts at Piper Jaffray issued an upgrade from Neutral to Overweight for the stock, in a research note that dated back to November 26.
NVAX stock has a trailing 3-year beta of 2.2, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.53 a share in the trailing twelve months. The stock’s value has surged 23.37 percent year to date (YTD) against a rise of 68.15 percent in 12 month’s time. The company’s shares still trade -17.45 percent away from its 1-year high of $2.75 and 97.39 percent up from 52-week low of $1.15. The average consensus rating on the company is 1.9, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
Shares of Novavax, Inc. (NVAX) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry NVAX operates in has an average P/E of 69.71. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 22.48 on the Price-to-Sales ratio. Compare this with the industry average P/S of 49.51. 0 percent is the gross profit margin for Novavax, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.
NVAX will be declaring its Q4 financial results on March 04. Analysts are forecasting revenue to suffer decline of -42.1 percent to $6.03M in the next fiscal quarter, while earnings are seen soaring by nearly -25 percent to -$0.12 per share. History has shown that shares in Novavax, Inc. have gone down on 23 different earnings reaction days and are predicted to add 0.06 percent when the company reports upcoming earnings. In last reported earnings results, it earned -$0.12 per share, in line with the -$0.12, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $7.74M, worse than the $9.4M analysts expected. Earnings are estimated to increase by 39.3 percent this year, 11.5 percent next year and continue to increase by 0 percent annually for the next 5 years.